EGFR and hepatocellular carcinoma: Importantly, the inhibition of EGFR with the tyrosine kinase inhibitor, gefitinib, exhibited an antitumoral effect in diethylnitrosamine (DEN) induced HCC rats suggesting that gefitinib is a potential drug for the HCC treatment [119].